BACK vs PTCT vs SRPT vs ATXI vs BMRN

For growth investors, PTC Therapeutics, Inc.

(PTCT) is the stronger pick with 114. 5% revenue growth year-over-year, versus -98. 6% for IMAC Holdings, Inc. (BACK). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 9. 5x trailing P/E, making it the more compelling value choice. Analysts rate PTC Therapeutics, Inc. (PTCT) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, PTC Therapeutics, Inc.

(PTCT) is the cheapest at 9. 5x versus BioMarin Pharmaceutical Inc. at 30. 0x. On forward P/E, Sarepta Therapeutics, Inc. is actually cheaper at 5. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, PTC Therapeutics, Inc.

(PTCT) delivered a total return of +89. 4%, compared to -100. 0% for Avenue Therapeutics, Inc. (ATXI). Over 10 years, the gap is even starker: PTCT returned +852. 1% versus ATXI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Avenue Therapeutics, Inc.

(ATXI) is the lower-risk stock at -0. 23β versus Sarepta Therapeutics, Inc. 's 1. 95β — meaning SRPT is approximately -944% more volatile than ATXI relative to the S&P 500. On balance sheet safety, BioMarin Pharmaceutical Inc. (BMRN) carries a lower debt/equity ratio of 11% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), PTC Therapeutics, Inc.

(PTCT) is pulling ahead at 114. 5% versus -98. 6% for IMAC Holdings, Inc. (BACK). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, PTCT leads at 35. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PTC Therapeutics, Inc.

(PTCT) is the more profitable company, earning 39. 4% net margin versus -125. 5% for IMAC Holdings, Inc. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -78. 0% for BACK. At the gross margin level — before operating expenses — ATXI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 5. 9x forward P/E versus 13. 6x for BioMarin Pharmaceutical Inc. — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMRN: 69. 3% to $91. 50.

In this comparison, BACK (100.

0% yield) pays a dividend. PTCT, SRPT, ATXI, BMRN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, IMAC Holdings, Inc.

(BACK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 04), 100. 0% yield). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BACK: -100. 0%, SRPT: +13. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BACK is a small-cap income-oriented stock; PTCT is a small-cap high-growth stock; SRPT is a small-cap high-growth stock; ATXI is a small-cap quality compounder stock; BMRN is a mid-cap quality compounder stock. BACK pays a dividend while PTCT, SRPT, ATXI, BMRN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.